BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Bringing Multi-Modal Intelligence to Early Clinical Recruitment

A protocol might specify a cohort defined by inflammatory markers, disease severity, a diagnostic pattern or a particular biological signature — but ...

December 10, 2025 | News | By Tom Stubbs, PHD – CEO of Hurdle.bio

SoluPet Partners With CHC To Launch Canine Cognitive Health Solution In Taiwan

SoluPet, the data and science-driven pet cognitive health company developing advanced cognitive-aging support for senior dogs, today announc...

December 10, 2025 | News

Replicate Bioscience Partners With Instituto Butantan To Advance Next Generation srRNA Rabies Vaccine Across Latin America

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunol...

December 05, 2025 | News

Kelun Biotech And Crescent Biopharma Forge Global Partnership To Advance Next Generation Oncology Therapies

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets an...

December 05, 2025 | News

Antengene Secures Expanded Approvals For Xpovio In Hong Kong Across Multiple Myeloma And DLBCL

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...

December 04, 2025 | News

Aurigene Oncology Reports Strong Early Phase One Results For AUR112 In Relapsed And Refractory Lymphomas

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, announced initial clinical results...

December 04, 2025 | News

AdvanCell Launches Theraphase Two Expansion To Optimise Dosing For ADVC001 Across Key Prostate Cancer Settings

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will ...

December 04, 2025 | News

Antengene Secures NMPA Approval for IND of CLINCH Two Combination Study in Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

December 03, 2025 | News

Fujitsu Develops Multi AI Agent Collaboration Technology for Secure and Resilient Supply Chains

Fujitsu Limited announced the development of a multi-AI agent collaboration technology that enables secure collaboration and swift response to changin...

December 02, 2025 | News

Generate Plans Global Phase 3 Trials for AI Engineered GB 0895 in Severe Asthma

Generate:Biomedicines ("Generate") announced it plans to initiate two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, evaluating GB-0895 in appr...

December 02, 2025 | News

IDEAYA Moves IDE034 Into Clinic Following FDA Clearance and Strong B7H3 PTK7 Co Expression

B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, r...

December 02, 2025 | News

Imugene and JW Therapeutics Launch First-in-Class “Mark and Kill” Solid Tumor Collaboration

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytic...

December 01, 2025 | News

Ascletis Advances First Oral Triple Agonist for Obesity, ASC37, into Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability ...

December 01, 2025 | News

Gan & Lee Launches Third Phase 3 Trial of Once-Monthly GLP-1 Bofanglutide for Long-Term Weight Maintenance

Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of...

November 28, 2025 | News

Stay Connected